Guardant Health (GH) Projected to Post Earnings on Wednesday

Guardant Health (NASDAQ:GH - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, July 30th. Analysts expect Guardant Health to post earnings of ($0.52) per share and revenue of $211.19 million for the quarter. Guardant Health has set its FY 2025 guidance at EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The firm had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. During the same period last year, the company earned ($0.46) EPS. The business's quarterly revenue was up 20.8% on a year-over-year basis. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Down 2.4%

Shares of Guardant Health stock traded down $1.07 during mid-day trading on Friday, hitting $44.42. The stock had a trading volume of 1,439,025 shares, compared to its average volume of 1,812,888. The firm has a 50-day moving average of $46.75 and a two-hundred day moving average of $44.69. Guardant Health has a 12-month low of $20.14 and a 12-month high of $53.42. The firm has a market cap of $5.50 billion, a P/E ratio of -13.10 and a beta of 1.44.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 3,213 shares of the company's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total transaction of $158,947.11. Following the completion of the sale, the director directly owned 7,190 shares in the company, valued at $355,689.30. This represents a 30.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ian T. Clark sold 6,672 shares of the firm's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares in the company, valued at approximately $476,591.38. This represents a 40.38% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 342,300 shares of company stock worth $17,082,238. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Guardant Health

An institutional investor recently bought a new position in Guardant Health stock. Empowered Funds LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,436 shares of the company's stock, valued at approximately $274,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GH shares. TD Securities increased their target price on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Stifel Nicolaus increased their target price on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Evercore ISI upgraded shares of Guardant Health to a "strong-buy" rating in a report on Monday, July 14th. Scotiabank restated an "outperform" rating on shares of Guardant Health in a report on Monday, May 5th. Finally, UBS Group raised their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $54.45.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.